Update on the non-huntington’s disease choreas with comments on the current nomenclature

Tremor and Other Hyperkinetic Movements

Volumn 2, Issue , 2012, Pages

  Walker, Ruth H ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Chorea; Neuroacanthocytosis; Neurodegeneration with brain iron accumulation

Indexed keywords

EID: 84903758295     PISSN: None     EISSN: 21608288     Source Type: Journal    
DOI: 10.5334/TOHM.122     Document Type: Article

References (117)

1. Walker RH. Differential diagnosis of chorea. Curr Neurol Neurosci Rep. 2011;11:385-395. doi: 10.1007/s11910-011-0202-2.
2. Walker RH. Oxford University Press; New YorkNY: The differential diagnosis of chorea. 2011.
3. Huntington Study Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72:971-983. doi: 10.1016/0092-8674(93)90585-E.
4. Andrew SE, Goldberg YP, Kremer B, et al. Huntington disease without cag expansion - phenocopies or errors in assignment. Am J Hum Genet. 1994;54:852-863.
5. Stevanin G, Fujigasaki H, Lebre AS, et al. Huntington's disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain. 2003;126:1599-1603. doi: 10.1093/brain/awg155.
6. Vuillaume I, Meynieu P, Schraen-Maschke S, et al. Absence of unidentified CAG repeat expansion in patients with Huntington's disease-like phenotype. J Neurol Neurosurg Psychiatry. 2000;68:672-675. doi: 10.1136/jnnp.68.5.672.
7. Xiang F, Almqvist EW, Huq M, et al. A Huntington disease-like neurodegenerative disorder maps to chromosome 20p. Am J Hum Genet. 1998;63:1431-1438.
8. Moore RC, Xiang F, Monaghan J, et al. Huntington disease phenocopy is a familial prion disease. Am J Hum Genet. 2001;69:1385-1388.
9. Laplanche JL, Hachimi KH, Durieux I, et al. Prominent psychiatric features and early onset in an inherited prion disease with a new insertional mutation in the prion protein gene. Brain. 1999;122:2375-2386. doi: 10.1093/brain/122.12.2375.
10. Margolis RL, O'Hearn E, Rosenblatt A, et al. A disorder similar to Huntington's disease is associated with a novel CAG repeat expansion. Ann Neurol. 2001;50:373-380.
11. Holmes SE, O'Hearn E, Rosenblatt A, et al. A repeat expansion in the gene encoding junctophilin-3 is associated with Huntington disease-like 2. Nat Genet. 2001;29:377-378. doi: 10.1038/ng760.
12. Wilburn B, Rudnicki DD, Zhao J, et al. An antisense CAG repeat transcript at JPH3 locus mediates expanded polyglutamine protein toxicity in Huntington's disease-like 2 mice. Neuron. 2011;70:427-440. doi: 10.1016/j.neuron.2011.03.021.
13. Rudnicki DD, Holmes SE, Lin MW, et al. Huntington's disease-like 2 is associated with CUG repeat-containing RNA foci. Ann Neurol. 2007;61:272-282. doi: 10.1002/ana.21081.
14. Rodrigues GG, Walker RH, Brice A, et al. Huntington's disease-like 2 in Brazil—Report of 4 patients. Mov Disord. 2008;23:2244-2247. doi: 10.1002/mds.22223.
15. Santos C, Wanderley H, Vedolin L, et al. Huntington disease-like 2: The first patient with apparent European ancestry. Clin Genet. 2008;73:480-485. doi: 10.1111/j.1399-0004.2008.00981.x.
16. Magazi DS, Krause A, Bonev V, et al. Huntington's disease: Genetic heterogeneity in black African patients. S Afr Med J. 2008;98:200-203.
17. Walker RH, Rasmussen A, Rudnicki D, et al. Huntington's Disease-like 2 can present as chorea-acanthocytosis. Neurology. 2003;61:1002-1004.
18. Kambouris M, Bohlega S, Al Tahan A, et al. Localization of the gene for a novel autosomal recessive neurodegenerative Huntington-like disorder to 4p15.3. Am J Hum Genet. 2000;66:445-452.
19. Richfield EK, Vonsattel JP, Macdonald ME, et al. Selective loss of striatal preprotachykinin neurons in a phenocopy of Huntington's disease. Mov Disord. 2002;17:327-332. doi: 10.1002/mds.10032.
20. Schneider SA, van de Warrenburg BP, Hughes TD, et al. Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family. Neurology. 2006;67:1701-1703. doi: 10.1212/01.wnl.0000242740.01273.00.
21. Namekawa M, Takiyama Y, Ando Y, et al. Choreiform movements in spinocerebellar ataxia type 1. J Neurol Sci. 2001;187:103-106. doi: 10.1016/S0022-510X(01)00527-5.
22. Geschwind DH, Perlman S, Figueroa CP, et al. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet. 1997;60:842-850.
23. Rottnek M, Riggio S, Byne W, et al. Schizophrenia in a patient with spinocerebellar ataxia 2: Coincidence of two disorders or a neurodegenerative disease presenting with psychosis? Am J Psychiatry. 2008;165:964-967.
24. Le Ber I, Camuzat A, Castelnovo G, et al. Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia. Arch Neurol. 2003;60:1097-1099. doi: 10.1001/archneur.60.8.1097.
25. Wardle M, Majounie E, Williams NM, et al. Dentatorubral pallidoluysian atrophy in South Wales. J Neurol Neurosurg Psychiatry. 2008;79:804-807. doi: 10.1136/jnnp.2007.128074.
26. Burke JR, Wingfield MS, Lewis KE, et al. The Haw River Syndrome: Dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. Nat Genet. 1994;7:521-524. doi: 10.1038/ng0894-521.
27. Levine IM, Estes JW, Looney JM. Hereditary neurological disease with acanthocytosis. A new syndrome. Arch Neurol. 1968;19:403-409. doi: 10.1001/archneur.1968.00480040069007.
28. Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol. 1968;18:134-140. doi: 10.1001/archneur.1968.00470320036004.
29. Hirose H. Neuroacanthocytosis in Japan—Review of the literature and cases. In: Walker RH, Saiki S, Danek A, editors. Neuroacanthocytosis Syndromes II. Springer-Verlag; Berlin Heidelberg: 2008. pp. 75-84.
30. Hardie RJ, Pullon HW, Harding AE, et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain. 1991;114:13-49.
31. Gandhi S, Hardie RJ, Lees AJ. An update on the Hardie neuroacanthocytosis series. In: Walker RH, Saiki S, Danek A, editors. Neuroacanthocytosis Syndromes II. Springer-Verlag; Berlin HeidelbergGermany: 2008. pp. 43-51.
32. Velayos-Baeza A, Holinski-Feder E, Nietzel B, et al. Chorea-acanthocytosis genotype in Critchley's original Kentucky neuroacanthocytosis kindred. Arch Neurol. 2011;68:1330-1333. doi: 10.1001/archneurol.2011.239.
33. Ueno S, Maruki Y, Nakamura M, et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet. 2001;28:121-122. doi: 10.1038/88825.
34. Rampoldi L, Dobson-Stone C, Rubio JP, et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet. 2001;28:119-120. doi: 10.1038/88821.
35. Velayos-Baeza A, Vettori A, Copley RR, et al. Analysis of the human VPS13 gene family. Genomics. 2004;84:536-549. doi: 10.1016/j.ygeno.2004.04.012.
36. Rampoldi L, Danek A, Monaco AP. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med. 2002;80:475-491.
37. Dobson-Stone C, Velayos-Baeza A, Filippone LA, et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol. 2004;56:299-302. doi: 10.1002/ana.20200.
38. Dobson-Stone C, Danek A, Rampoldi L, et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet. 2002;10:773-781.
39. Sorrentino G, De Renzo A, Miniello S, et al. Late appearance of acanthocytes during the course of chorea-acanthocytosis. J Neurol Sci. 1999;163:175-178. doi: 10.1016/S0022-510X(99)00005-2.
40. Bayreuther C, Borg M. Chorea-acanthocytosis: A diagnosis not to be ruled out in absence of acanthocytes. J Neurol. 2008;255:98.
41. Malandrini A, Fabrizi GM, Palmeri S, et al. Choreo-acanthocytosis like phenotype without acanthocytes: Clinicopathological case report. A contribution to the knowledge of the functional pathology of the caudate nucleus. Acta Neuropathol (Berl) 1993;86:651-658. doi: 10.1007/BF00294306.
42. Symmans WA, Shepherd CS, Marsh WL, et al. Hereditary acanthocytosis associated with the McLeod phenotype of the Kell blood group system. Br J Haematol. 1979;42:575-583.
43. Redman CM, Russo D, Lee S. Kell, Kx and the McLeod syndrome. Baillieres Best Pract Res Clin Haematol. 1999;12:621-635. doi: 10.1053/beha.1999.0045.
44. Danek A, Rubio JP, Rampoldi L, et al. McLeod neuroacanthocytosis: Genotype and phenotype. Ann Neurol. 2001;50:755-764. doi: 10.1002/ana.10035.
45. Jung HH, Hergersberg M, Kneifel S, et al. McLeod syndrome: A novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol. 2001;49:384-392. doi: 10.1002/ana.76.
46. Danek A, Tison F, Rubio J, et al. The chorea of McLeod syndrome. Mov Disord. 2001;16:882-889. doi: 10.1002/mds.1188.
47. Walker RH, Danek A, Uttner I, et al. McLeod phenotype without the McLeod syndrome. Transfusion. 2006;47:299-305. doi: 10.1111/j.1537-2995.2007.01106.x.
48. Oechslin E, Kaup D, Jenni R, et al. Cardiac abnormalities in McLeod syndrome. Int J Cardiol. 2009;132:130-132.
49. Hayflick SJ, Westaway SK, Levinson B, et al. Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome. N Engl J Med. 2003;348:33-40.
50. Orrell RW, Amrolia PJ, Heald A, et al. Acanthocytosis, retinitis pigmentosa, and pallidal degeneration: A report of three patients, including the second reported case with hypoprebetalipoproteinemia (HARP syndrome). Neurology. 1995;45:487-492.
51. Zhou B, Westaway SK, Levinson B, et al. A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet. 2001;28:345-349. doi: 10.1038/ng572.
52. Shevell MI, Peiffer J. Julius Hallervorden's wartime activities: Implications for science under dictatorship. Pediatr Neurol. 2001;25:162-165. doi: 10.1016/S0887-8994(00)00243-5.
53. Shevell M. Hallervorden and history. N Engl J Med. 2003;348:3-4.
54. Malandrini A, Cesaretti S, Mulinari M, et al. Acanthocytosis, retinitis pigmentosa, pallidal degeneration. Report of two cases without serum lipid abnormalities. J Neurol Sci. 1996;140:129-131. doi: 10.1016/0022-510X(96)00155-4.
55. Curtis AR, Fey C, Morris CM, et al. Mutation in the gene encoding ferritin light polypeptide causes dominant adult-onset basal ganglia disease. Nat Genet. 2001;28:350-354. doi: 10.1038/ng571.
56. Crompton DE, Chinnery PF, Bates D, et al. Spectrum of movement disorders in neuroferritinopathy. Mov Disord. 2004;20:95-99. doi: 10.1002/mds.20284.
57. Mir P, Edwards MJ, Curtis AR, et al. Adult-onset generalized dystonia due to a mutation in the neuroferritinopathy gene. Mov Disord. 2004;20:243-245. doi: 10.1002/mds.20280.
58. Kubota A, Hida A, Ichikawa Y, et al. A novel ferritin light chain gene mutation in a Japanese family with neuroferritinopathy: Description of clinical features and implications for genotype-phenotype correlations. Mov Disord. 2009;24:441-445. doi: 10.1002/mds.22435.
59. Xu X, Pin S, Gathinji M, et al. Aceruloplasminemia: An inherited neurodegenerative disease with impairment of iron homeostasis. Ann N Y Acad Sci. 2004;1012:299-305. doi: 10.1196/annals.1306.024.
60. Miyajima H. Aceruloplasminemia, an iron metabolic disorder. Neuropathology. 2003;23:345-350. doi: 10.1046/j.1440-1789.2003.00521.x.
61. McNeill A, Pandolfo M, Kuhn J, et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol. 2008;60:200-205. doi: 10.1159/000148691.
62. McNeill A, Birchall D, Hayflick SJ, et al. T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation. Neurology. 2008;70:1614-1619. doi: 10.1212/01.wnl.0000310985.40011.d6.
63. Morgan NV, Westaway SK, Morton JE, et al. PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron. Nat Genet. 2006;38:752-754. doi: 10.1038/ng1826.
64. Gregory A, Westaway SK, Holm IE, et al. Neurodegeneration associated with genetic defects in phospholipase A(2). Neurology. 2008;71:1402-1409. doi: 10.1212/01.wnl.0000327094.67726.28.
65. Mubaidin A, Roberts E, Hampshire D, et al. Karak syndrome: A novel degenerative disorder of the basal ganglia and cerebellum. J Med Genet. 2003;40:543-546. doi: 10.1136/jmg.40.7.543.
66. Schneider SA, Paisan-Ruiz C, Quinn NP, et al. ATP13A2 mutations (PARK9) cause neurodegeneration with brain iron accumulation. Mov Disord. 2010;25:979-984. doi: 10.1002/mds.22947.
67. Kruer MC, Paisan-Ruiz C, Boddaert N, et al. Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol. 2010;68:611-618. doi: 10.1002/ana.22122.
68. Breedveld GJ, van Dongen JW, Danesino C, et al. Mutations in TITF-1 are associated with benign hereditary chorea. Hum Mol Genet. 2002;11:971-979. doi: 10.1093/hmg/11.8.971.
69. Mahajnah M, Inbar D, Steinmetz A, et al. Benign hereditary chorea: Clinical, neuroimaging, and genetic findings. J Child Neurol. 2007;22:1231-1234. doi: 10.1177/0883073807306261.
70. Devos D, Vuillaume I, De Becdelievre A, et al. New syndromic form of benign hereditary chorea is associated with a deletion of TITF-1 and PAX-9 contiguous genes. Mov Disord. 2006;21:2237-2240. doi: 10.1002/mds.21135.
71. Bauer P, Kreuz FR, Burk K, et al. Mutations in TITF1 are not relevant to sporadic and familial chorea of unknown cause. Mov Disord. 2006;21:1734-1737. doi: 10.1002/mds.21031.
72. Schrag A, Quinn NP, Bhatia KP, et al. Benign hereditary chorea—Entity or syndrome? Mov Disord. 2000;15:280-288. doi: 10.1002/1531-8257(200003)15:2<280::AID-MDS1011>3.0.CO;2-Q.
73. Asmus F, Horber V, Pohlenz J, et al. A novel TITF-1 mutation causes benign hereditary chorea with response to levodopa. Neurology. 2005;64:1952-1954. doi: 10.1212/01.WNL.0000164000.75046.CC.
74. Kleiner-Fisman G, Calingasan NY, Putt M, et al. Alterations of striatal neurons in benign hereditary chorea. Mov Disord. 2005;20:1353-1357. doi: 10.1002/mds.20577.
75. Maccabelli G, Pichiecchio A, Guala A, et al. Advanced magnetic resonance imaging in benign hereditary chorea: Study of two familial cases. Mov Disord. 2010;25:2670-2674. doi: 10.1002/mds.23281.
76. Salvatore E, Di Maio L, Filla A, et al. Benign hereditary chorea: Clinical and neuroimaging features in an Italian family. Mov Disord. 2010;25:1491-1496. doi: 10.1002/mds.23065.
77. Krude H, Schutz B, Biebermann H, et al. Choreoathetosis, hypothyroidism, and pulmonary alterations due to human NKX2-1 haploinsufficiency. J Clin Invest. 2002;109:475-480.
78. Ferrara AM, De Michele G, Salvatore E, et al. A novel NKX2.1 mutation in a family with hypothyroidism and benign hereditary chorea. Thyroid. 2008;18:1005-1009. doi: 10.1089/thy.2008.0085.
79. Willemsen MA, Breedveld GJ, Wouda S, et al. Brain-thyroid-lung syndrome: A patient with a severe multi-system disorder due to a de novo mutation in the thyroid transcription factor 1 gene. Eur J Pediatr. 2005;164:28-30.
80. Kujawa KA, Niemi VR, Tomasi MA, et al. Ballistic-choreic movements as the presenting feature of renal cancer. Arch Neurol. 2001;58:1133-1135. doi: 10.1001/archneur.58.7.1133.
81. Tani T, Piao Y, Mori S, et al. Chorea resulting from paraneoplastic striatal encephalitis. J Neurol Neurosurg Psychiatry. 2000;69:512-515. doi: 10.1136/jnnp.69.4.512.
82. Batchelor TT, Platten M, Palmer-Toy DE, et al. Chorea as a paraneoplastic complication of Hodgkin's disease. J Neurooncol. 1998;36:185-190. doi: 10.1023/A:1005860103173.
83. Vernino S, Tuite P, Adler CH, et al. Paraneoplastic chorea associated with CRMP-5 neuronal antibody and lung carcinoma. Ann Neurol. 2002;51:625-630. doi: 10.1002/ana.10178.
84. Dorban S, Gille M, Kessler R, et al. [Chorea-athetosis in the anti-Hu syndrome]. Rev Neurol (Paris) 2004;160:126-129. doi: 10.1016/S0035-3787(04)70863-2.
85. Honnorat J, Cartalat-Carel S, Ricard D, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009;80:412-416. doi: 10.1136/jnnp.2007.138016.
86. Krolak-Salmon P, Androdias G, Meyronet D, et al. Slow evolution of cerebellar degeneration and chorea in a man with anti-Yo antibodies. Eur J Neurol. 2006;13:307-308.
87. Luca N, Daengsuwan T, Dalmau J, et al. Anti-N-methyl-D-aspartate receptor encephalitis: A newly recognized inflammatory brain disease in children. Arthritis Rheum. 2011;63:2515-2522. doi: 10.1002/art.30437.
88. Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63-74. doi: 10.1016/S1474-4422(10)70253-2.
89. Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866-5875. doi: 10.1523/JNEUROSCI.0167-10.2010.
90. Vincent A, Bien CG. Anti-NMDA-receptor encephalitis: A cause of psychiatric, seizure, and movement disorders in young adults. Lancet Neurol. 2008;7:1074-1075. doi: 10.1016/S1474-4422(08)70225-4.
91. Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25-36. doi: 10.1002/ana.21050.
92. Lahiri N, Mead S, Tabrizi SJ. Chorea in the prion diseases. In: Walker RH, editor. The differential diagnosis of chorea. Oxford University Press; New York: 2011. pp. 188-205.
93. Bowen J, Mitchell T, Pearce R, et al. Chorea in new variant Creutzfeldt-Jacob disease. Mov Disord. 2000;15:1284-1285. doi: 10.1002/1531-8257(200011)15:6<1284::AID-MDS1043>3.0.CO;2-Y.
94. McKee D, Talbot P. Chorea as a presenting feature of variant Creutzfeldt-Jakob disease. Mov Disord. 2003;18:837-838. doi: 10.1002/mds.10423.
95. Yianni J, Nandi D, Bradley K, et al. Senile chorea treated by deep brain stimulation: A clinical, neurophysiological and functional imaging study. Mov Disord. 2004;19:597-602. doi: 10.1002/mds.10716.
96. Burbaud P, Rougier A, Ferrer X, et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord. 2002;17:204-207. doi: 10.1002/mds.1260.
97. Wihl G, Volkmann J, Allert N, et al. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord. 2001;16:572-575. doi: 10.1002/mds.1109.
98. Ruiz PJ, Ayerbe J, Bader B, et al. Deep brain stimulation in chorea acanthocytosis. Mov Disord. 2009;24:1546-1547. doi: 10.1002/mds.22592.
99. Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord. 2005;20:1681-1682.
100. Watarai M, Hashimoto T, Yamamoto K, et al. Pallidotomy for severe generalized chorea of juvenile-onset dentatorubral-pallidoluysian atrophy. Neurology. 2003;61:1452-1454.
101. Fujimoto Y, Isozaki E, Yokochi F, et al. [A case of chorea-acanthocytosis successfully treated with posteroventral pallidotomy]. Rinsho Shinkeigaku. 1997;37:891-894.
102. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38:391-394.
103. Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord. 2003;18:703-706. doi: 10.1002/mds.10427.
104. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology. 1988;27:717-719. doi: 10.1016/0028-3908(88)90080-9.
105. Moss JH, Stewart DE. Iatrogenic parkinsonism in Huntington's chorea. Can J Psychiatry. 1986;31:865-866.
106. Lin FC, Wei LJ, Shih PY. Effect of levetiracetam on truncal tic in neuroacanthocytosis. Acta Neurol Taiwan. 2006;15:38-42.
107. Al-Asmi A, Jansen AC, Badhwar A, et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia. 2005;46:1256-1263. doi: 10.1111/j.1528-1167.2005.65804.x.
108. Lucetti C, Del Dotto P, Gambaccini G, et al. IV amantadine improves chorea in Huntington's disease: An acute randomized, controlled study. Neurology. 2003;60:1995-1997.
109. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: A randomized, controlled trial using the NMDA-antagonist amantadine. Neurology. 2002;59:694-699.
110. O'suilleabhain P, Dewey RB., Jr A randomized trial of amantadine in Huntington disease. Arch Neurol. 2003;60:996-998. doi: 10.1001/archneur.60.7.996.
111. Rosas HD, Koroshetz WJ, Jenkins BG, et al. Riluzole therapy in Huntington's disease (HD). Mov Disord. 1999;14:326-330. doi: 10.1002/1531-8257(199903)14:2<326::AID-MDS1019>3.0.CO;2-Q.
112. Seppi K, Mueller J, Bodner T, et al. Riluzole in Huntington's disease (HD): An open label study with one year follow up. J Neurol. 2001;248:866-869.
113. Henkel K, Danek A, Grafman J, et al. Head of the caudate nucleus is most vulnerable in chorea-acanthocytosis: A voxel-based morphometry study. Mov Disord. 2006;21:1728-1731. doi: 10.1002/mds.21046.
114. Huppertz HJ, Kroll-Seger J, Danek A, et al. Automatic striatal volumetry allows for identification of patients with chorea-acanthocytosis at single subject level. J Neural Transm. 2008;115:1393-1400. doi: 10.1007/s00702-008-0094-8.
115. Walterfang M, Looi JC, Styner M, et al. Shape alterations in the striatum in chorea-acanthocytosis. Psychiatry Res. 2011;192:29-36. doi: 10.1016/j.pscychresns.2010.10.006.
116. Valko PO, Hanggi J, Meyer M, et al. Evolution of striatal degeneration in McLeod syndrome. Eur J Neurol. 2010;17:612-618.
117. Ismailogullari S, Caglayan AO, Bader B, et al. Magnetic resonance spectroscopy in two siblings with chorea-acanthocytosis. Mov Disord. 2010;25:2894-2897. doi: 10.1002/mds.23365.